Eli Lilly
—
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries.
From Wikipedia, CC BY-SA 4.0, revision of 13 Oct 2026.
What stands out
- Sales have grown about 21.6% a year for five years, so each $1 of sales in FY2020 is about $2.66 now.Revenue growth over 5–10 years: +21.6% a year
Worth digging into
- Eli Lilly owes more than it holds in cash, and its free cash flow didn't cover that last year.Net debt ÷ EBITDA or ÷ FCF, plus interest cover: Net debt $46.0B
From filed figures and the weekly screener snapshot, 30 Oct 2026. Observations to check in the tabs below, not advice.
What has the price done?
—
Press and drag across the chart to see the change between two points. Source: Yahoo Finance, delayed. Bars are daily and prices are adjusted for splits, not dividends. Past returns don't predict future returns.
Dividends
Full chart
TradingView's advanced chart, with indicators and drawing tools. It loads when you scroll to it.
How does it make money?
What it does is in the oven
We haven't typed up Eli Lilly's business and region split yet. Every figure comes from the company's own results, so this takes a little time.
See companies we've covered ›History and context
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
From Wikipedia's article Eli Lilly and Company, the lead section as of the revision of 13 Oct 2026, retrieved 1 Nov 2026. Text under CC BY-SA 4.0, pronunciation guides removed. Wikipedia can be edited by anyone; the company's own filings are the primary source.
What it actually sells Soon
A product-by-product guide to Eli Lilly: what each one is, who buys it, and how much it brings in, in plain English and in the company's own terms. We're starting with the companies that are hardest to picture, like Broadcom.
Moat not rated yet
We haven't rated Eli Lilly's moat. A rating needs at least five years of returns against the cost of capital, plus evidence for each of the five lenses.
How we rate moats ›Is it a good business at a fair price?
What each method implies
Ranges, not targetsThe five questions, and the price
Six checks from the annual reports. A flag marks a reason to dig deeper, not a verdict.
- 1. Is it growing?Within the guide
+21.6% a year
Revenue growth over 5–10 years
Revenue $24.5B in FY2020 to $65.2B in FY2025; +12.6% a year over 10 years. It fell in 0 of the last 5 years.
Sales have grown about 21.6% a year for five years, so each $1 of sales in FY2020 is about $2.66 now.
What to look for Steady growth, not one lucky year.
Source: FY2020 10-K, filed 17 Feb 2021; FY2025 10-K, filed 12 Feb 2026.
- 2. Is it profitable?
—
Operating margin (operating income ÷ revenue)
Operating income isn't tagged in the 10-K.
We need operating income and revenue to answer this.
What to look for Stable or rising. It's cleaner than net income, which one-off items and tax can distort.
- 3. Is the profit real cash?
—
Free cash flow (operating cash flow − capex), and FCF ÷ net income
Operating cash flow or capex isn't tagged in the 10-K.
We need the cash flow statement to answer this.
What to look for FCF positive and growing, and close to net income over time.
- 4. Is it a good business?
—
Return on invested capital (ROIC); ROE for banks
Equity, debt or cash isn't tagged for enough years to work out ROIC.
We need the balance sheet to answer this.
What to look for Clearly above the cost of capital (roughly 8–10%). Sustained 15%+ usually means a moat.
- 5. Can it survive a bad year?Reason to dig deeper
Net debt $46.0B
Net debt ÷ EBITDA or ÷ FCF, plus interest cover
the Stock valuation sheet, https://stockanalysis.com/stocks/lly/statistics/, debt including leases: borrowings $54.9B, cash and short-term investments $8.9B, net debt $46.0B. Interest cover: —.
Eli Lilly owes more than it holds in cash, and its free cash flow didn't cover that last year.
What to look for Debt payable from about 3 years of FCF or less, interest covered many times.
Source: FY2025 10-K, filed 12 Feb 2026; the Stock valuation sheet, https://stockanalysis.com/stocks/lly/statistics/, debt including leases.
- 6. Is the price right?
−21.0% vs the sheet
FCF yield or EV/EBIT, and price against a cash-flow value
Market cap $1.3T. The valuation sheet's default story values it at US$1239.16–US$2020.31 a share (middle US$1591.90); at US$1257.03, its 16 Oct 2026 price, the price is −21.0% against the middle.
On the sheet's default story the price sits below the middle of its value range, by 21%. Change the story and that moves.
What to look for Pay less than a cash-flow value estimate, with a margin of safety.
Source: Price $1417.54, Yahoo Finance weekly snapshot, 30 Oct 2026; 941M shares, 10-Q 3 Aug 2026; FY2025 10-K, filed 12 Feb 2026; Stock valuation, 16 Oct 2026.
US figures: each company's Form 10-K as tagged on SEC EDGAR, collected 19 Oct 2026. Free cash flow is operating cash flow less purchases of property and equipment. Borrowings exclude leases. For education only. Not financial advice.
Ten years of financials
FY2016 to FY2025, in US dollars.
Source: Eli Lilly, Form 10-K for each year as first filed, via SEC EDGAR XBRL. Latest: FY2025 10-K, filed 12 Feb 2026. Later restatements aren't applied.
How peers compare
Big pharmaDrugmakers are compared on pipeline-driven growth; patent cliffs make a single year's multiple noisier than usual.
| Company | Revenue growth, 5y | Operating margin | P/E |
|---|---|---|---|
| LLY | +21.6% a year | — | 61.8x |
| JNJ | +2.7% a year | — | 24.8x |
| ABBV | +6.0% a year | 24.6% | 125.0x |
| PFE | +8.5% a year | — | 22.4x |
- Peers' middle-half P/E
- 23.6x–74.9x (median 24.8x, 3 peers)
At the peers' middle-half P/E, Eli Lilly's earnings per share from the FY2025 10-K would put the share between $542 and $1,718. Those are the peer bars in the valuation chart above — one way to read the price, not a target.
Prices: weekly screener snapshot, 30 Oct 2026. Profits: each company's latest annual filing via SEC EDGAR, as filed. Peers are hand-picked for this industry. A multiple compares one year's profit with today's price; it says nothing about what either does next.
Discounted cash flow, from Stock valuation
Ten years of free cash flow to the firm, from Eli Lilly's latest figures and Damodaran's industry averages (Drugs (Pharmaceutical)). It's one story told with numbers, so it comes as a range.
- Value range, the default story$1,239.16–$2,020.31Middle $1,591.90 a share
- Price, 16 Oct 2026 close$1,257.03−21.04% ▼ against the middle
- What the price implies17.7% a yearGrowth in years 2–5 that makes value equal the price; the story uses 22.1%
To be worth today's price, Eli Lilly would need to grow sales about 17.7% a year in years 2–5. One way to read this is to ask whether that sounds believable.
The story's assumptions
- Revenue, last 12 months
- $79,666M
- Operating margin now
- 49.7%
- Revenue growth, year 1
- 25.7%
- Revenue growth, years 2–5
- 22.1%
- Growth after year 10
- 5.1%
- Target operating margin, by year 5
- 49.7%
- Sales to capital, years 1–5 / 6–10
- 1.11 / 1.11
- Tax rate now / after year 10
- 20.5% / 25.0%
- Cost of capital, years 1–5
- 8.9%
- Cost of capital after year 10
- 8.7%
- Return on capital after year 10
- 12.8%
- Chance of failure
- 0.0%
Value per share as two inputs change (revenue growth, years 2–5 down, target operating margin across)
| Revenue growth, years 2–5 | 44.7% | 49.7% | 54.7% |
|---|---|---|---|
| 19.1% | $1,239.16 | $1,391.71 | $1,544.26 |
| 22.1% | $1,416.12 | $1,591.90 | $1,767.68 |
| 25.1% | $1,616.20 | $1,818.25 | $2,020.31 |
Middle cell: the default story. Each step is 3 points of growth or 5 points of margin.
| Year | Growth | Revenue | Margin | Operating income | Tax rate | After-tax income | Reinvestment | Free cash flow | Cost of capital | Present value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 25.7% | $100,136M | 49.7% | $49,785M | 20.5% | $39,584M | $18,413M | $21,171M | 8.9% | $19,444M |
| 2 | 22.1% | $122,239M | 49.7% | $60,774M | 20.5% | $48,322M | $19,882M | $28,440M | 8.9% | $23,989M |
| 3 | 22.1% | $149,220M | 49.7% | $74,189M | 20.5% | $58,987M | $24,270M | $34,717M | 8.9% | $26,895M |
| 4 | 22.1% | $182,156M | 49.7% | $90,564M | 20.5% | $72,007M | $29,627M | $42,380M | 8.9% | $30,154M |
| 5 | 22.1% | $222,363M | 49.7% | $110,553M | 20.5% | $87,901M | $36,167M | $51,734M | 8.9% | $33,807M |
| 6 | 18.7% | $263,891M | 49.7% | $131,200M | 21.4% | $103,134M | $37,356M | $65,778M | 8.8% | $39,491M |
| 7 | 15.3% | $304,213M | 49.7% | $151,247M | 22.3% | $117,528M | $36,270M | $81,258M | 8.8% | $44,837M |
| 8 | 11.9% | $340,362M | 49.7% | $169,220M | 23.2% | $129,968M | $32,517M | $97,450M | 8.8% | $49,438M |
| 9 | 8.5% | $369,247M | 49.7% | $183,581M | 24.1% | $139,341M | $25,983M | $113,359M | 8.7% | $52,892M |
| 10 | 5.1% | $388,042M | 49.7% | $192,925M | 25.0% | $144,694M | $16,906M | $127,787M | 8.7% | $54,857M |
| After 10 | 5.1% | $407,793M | 49.7% | $202,745M | 25.0% | $152,059M | $60,373M | $91,686M | 8.7% | $1,093,312M |
- Present value of years 1–10
- $375,804M
- Present value after year 10
- $1,093,312M
- Less debt, plus cash
- −$45,958M
- Value of equity
- $1,423,158M
- Shares
- 894M
- Value per share, default story
- $1,591.90
Company figures: https://stockanalysis.com/stocks/lly/statistics/, TTM to Jun 2026. Industry averages: Aswath Damodaran, January 2026 US data. Risk-free rates: US 10-year Treasury 5.09% and Singapore 10-year 2.34%, 16 Oct 2026. Equity risk premium: Damodaran's implied premium of 4.20%, 1 Oct 2026. Company figures are the latest reported before 19 Oct 2026. Data as of 16 Oct 2026. The sheet follows the spreadsheets Aswath Damodaran publishes; it is not affiliated with or endorsed by him. A model's value is not a price target. For education only. Not financial advice.
Who owns it, and what's the mood?
Tracked investors and insiders
Trades in Eli Lilly by the people we follow: Warren Buffett and Michael Burry (13F), Grab's officers (Form 4) and Nancy Pelosi (House reports). They show what happened, often weeks later, not what to copy.
| Who | Did | Size | When | Disclosed |
|---|---|---|---|---|
| Cathie WoodARK Investment Management | AddedShares | +64,578 sharesabout $77,456,791 at quarter-end value | Q2 2026 | 14 Aug 202645 days after Q2 2026 ended |
Sources: SEC EDGAR 13F-HR and Form 4 filings, and the US House Clerk's Periodic Transaction Reports, checked 30 Oct 2026. 13F values are the quarter-end value, not the price paid. All tracked trades ›
- Largest shareholdersSoonThe biggest holders from 13F filings and the annual proxy statement.—
- Chief executive and board holdingsSoonShares held by the CEO and directors, from the proxy statement and Form 4s.—
- Short interestSoonHow many shares are sold short, from exchange short-interest reports.—
Crowd favourite or value trap?
Neither is a label we can put on a stock. These are signs worth looking into, each from a figure on this page.
Signs of a crowd-driven price
Meme stocks move on attention more than on results: big swings, a price far from cash-flow value, thin profits.
0 of 3 signs (1 without data)
- NoSwings at least twice as much as the marketBeta 0.39, 5 years of monthly returns
- NoUp more than 100%, or down more than 50%, in a year1-year price change +65.32%
- NoPrice more than 50% above the valuation sheet's middle valuePrice −21% against the sheet's default story, 16 Oct 2026
- —Thin profits: operating margin under 5%, or a lossNo operating margin yet
Signs of a value trap
A value trap looks cheap because the business is shrinking or earning less than its capital costs.
0 of 3 signs (1 without data)
- NoLooks cheap: P/E under 12 or FCF yield over 8%P/E 61.8x
- NoRevenue lower than five years agoRevenue +21.6% a year over 5 years
- —Returns below the cost of capitalNot rated yet
- NoMore than 30% below its 52-week high−2.2% from the 52-week high
Prices, beta and 1-year change: Yahoo Finance weekly snapshot, 30 Oct 2026. Business figures: the five questions under Valuation and financials. A sign is a reason to dig deeper, not a verdict. For education only. Not financial advice.
Read it through a lens
Price data: Yahoo Finance, delayed. Company figures: each company's own filings, dated where they appear. A ticker on this site is not a recommendation. For education only. Not financial advice.